{"id":"W3100553135","doi":"10.1016/j.annonc.2020.10.596","title":"Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":163,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Fulvestrant; Medicine; Placebo; Hazard ratio; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Aromatase inhibitor; Metastatic breast cancer; Cancer; Estrogen receptor; Randomized controlled trial; Gynecology; Confidence interval; Aromatase; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075095,0.0002856844,0.001100316,0.00005351994,0.00005684951,0.000008502713,0.000394682,0.0001854846,0.0001559158],"category_scores_gemma":[0.0002888914,0.0001797327,0.000164706,0.0003001156,0.0004677163,0.00001183561,0.00009034242,0.00022822,0.000001186346],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002777926,"about_ca_system_score_gemma":0.0007224271,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004942975,"about_ca_topic_score_gemma":0.0005230416,"domain_scores_codex":[0.9972193,0.0008836709,0.0007898174,0.000509178,0.0002562016,0.0003418165],"domain_scores_gemma":[0.9982259,0.0004015032,0.0006159387,0.0003155321,0.0003196137,0.0001215384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8593935,0.001840734,0.0001689489,0.00002367415,0.0006365338,0.00002536863,0.001485104,0.0009583721,0.1273354,0.00001073755,0.0007860389,0.007335516],"study_design_scores_gemma":[0.727251,0.02741675,0.00005793139,0.00006725679,0.0001541458,0.00001755632,0.001614644,0.00008592029,0.2407263,0.00001131822,0.002343207,0.0002539992],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99374,0.0005600379,0.0001274768,0.00218776,0.0001554059,0.0025814,0.0003662106,0.000009333408,0.0002723492],"genre_scores_gemma":[0.9973501,0.0007714583,0.0002485164,0.0008048117,0.0002568869,0.0004683821,0.00003965745,0.00003225672,0.00002791323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1321426,"threshold_uncertainty_score":0.7329288,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03981314504028136,"score_gpt":0.3696024707202757,"score_spread":0.3297893256799943,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}